Literature DB >> 21501546

Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management.

Jack Barkin1.   

Abstract

Significant lower urinary tract symptoms (LUTS) are very common in men over age 50. It is appropriate for the primary care physician to perform the work up to confirm that benign prostatic hyperplasia (BPH) is causing the LUTS. If the physician determines that the patient has moderate symptoms (an International Prostate Symptom Score [IPSS] ≥ 8), moderate 'bother' (≥ 3 on the IPSS "bothersome index" question), and an enlarged (> 30 cc) prostate, then the most effective treatment is combination therapy with an alpha blocker and 5-alpha reductase inhibitor (5-ARI) at the time of confirmed BPH diagnosis. This combination will provide the most dramatic, early symptom response, the most sustained symptom response, and the most durable, reliable prevention of long term sequelae (acute urinary retention or the need for surgery), if the patient is compliant with taking the combination therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21501546

Source DB:  PubMed          Journal:  Can J Urol        ISSN: 1195-9479            Impact factor:   1.344


  19 in total

1.  Optimizing the management of benign prostatic hyperplasia.

Authors:  Dean S Elterman; Jack Barkin; Steven A Kaplan
Journal:  Ther Adv Urol       Date:  2012-04

2.  Bacteriological Profile of Isolates From Urine Samples in Patients of Benign Prostatic Hyperplasia and or Prostatitis Showing Lower Urinary Tract Symptoms.

Authors:  Prem Prakash Mishra; Ved Prakash; Kashmir Singh; H Mog; Sumit Agarwal
Journal:  J Clin Diagn Res       Date:  2016-10-01

Review 3.  Stromal androgen receptor roles in the development of normal prostate, benign prostate hyperplasia, and prostate cancer.

Authors:  Simeng Wen; Hong-Chiang Chang; Jing Tian; Zhiqun Shang; Yuanjie Niu; Chawnshang Chang
Journal:  Am J Pathol       Date:  2014-11-26       Impact factor: 4.307

4.  Urine flow acceleration is superior to Qmax in diagnosing BOO in patients with BPH.

Authors:  Jian-Guo Wen; Lin-Gang Cui; Yi-Dong Li; Xiao-Ping Shang; Wen Zhu; Rui-Li Zhang; Qing-Jun Meng; Sheng-Jun Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-08-01

Review 5.  The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin.

Authors:  Júlio Fonseca; Carlos Martins da Silva
Journal:  Clin Drug Investig       Date:  2015-02       Impact factor: 2.859

6.  Physical activity for lower urinary tract symptoms secondary to benign prostatic obstruction.

Authors:  Valter Silva; Antonio Jose Grande; Maria S Peccin
Journal:  Cochrane Database Syst Rev       Date:  2019-04-06

Review 7.  Androgen receptor roles in the development of benign prostate hyperplasia.

Authors:  Kouji Izumi; Atsushi Mizokami; Wen-Jye Lin; Kuo-Pao Lai; Chawnshang Chang
Journal:  Am J Pathol       Date:  2013-04-06       Impact factor: 4.307

8.  Inhibitory effect of Yukmijihwang-tang, a traditional herbal formula against testosterone-induced benign prostatic hyperplasia in rats.

Authors:  In Sik Shin; Mee Young Lee; Hye Kyung Ha; Chang Seob Seo; Hyeun-Kyoo Shin
Journal:  BMC Complement Altern Med       Date:  2012-04-20       Impact factor: 3.659

9.  The influence of depression, anxiety and somatization on the clinical symptoms and treatment response in patients with symptoms of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

Authors:  Yong June Yang; Jun Sung Koh; Hyo Jung Ko; Kang Joon Cho; Joon Chul Kim; Soo-Jung Lee; Chi-Un Pae
Journal:  J Korean Med Sci       Date:  2014-07-30       Impact factor: 2.153

10.  Cinnamomi Cortex (Cinnamomum verum) Suppresses Testosterone-induced Benign Prostatic Hyperplasia by Regulating 5α-reductase.

Authors:  Hyun-Myung Choi; Yunu Jung; Jinbong Park; Hye-Lin Kim; Dong-Hyun Youn; JongWook Kang; Mi-Young Jeong; Jong-Hyun Lee; Woong Mo Yang; Seok-Geun Lee; Kwang Seok Ahn; Jae-Young Um
Journal:  Sci Rep       Date:  2016-08-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.